What is Oxitec?
Oxitec is a biotechnology company focused on developing environmentally friendly insect control solutions. Its core technology involves a non-biting male mosquito designed to control invasive, disease-spreading Aedes aegypti populations. This innovative approach has demonstrated significant suppression of Aedes aegypti in various geographies, offering a sustainable alternative to traditional methods. The technology eliminates the need for adult mosquito rearing and releases, thereby reducing costs associated with insect release programs by up to 90%. Previous projects have shown up to a 95% suppression rate of disease-carrying mosquitoes in urban, dengue-prone environments.
How much funding has Oxitec raised?
Oxitec has raised a total of $35.2M across 5 funding rounds:
Private Equity
$2.6M
Private Equity
$3M
Private Equity
$12.6M
Private Equity
$10.2M
Private Equity
$6.8M
Private Equity (2005): $2.6M with participation from Oxford Capital Partners, East Hill Management Company, LLC, and Oxford University
Private Equity (2007): $3M led by East Hill Management Company, LLC and Oxford Capital Partners
Private Equity (2012): $12.6M supported by Oxford Capital Partners and Asia Pacific Capital
Private Equity (2014): $10.2M featuring Oxford Capital Partners, Oxford University, and East Hill Management
Private Equity (2021): $6.8M backed by The Wellcome Trust
Key Investors in Oxitec
The Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to supporting discovery research and addressing urgent health challenges through grants, partnerships, and public engagement, focusing on improving global health outcomes.
Oxford Capital Partners
Oxford Capital Partners is an investment manager providing growth capital to smaller companies across various industries, with a focus on helping entrepreneurs expand their businesses and a history of investing in university spinouts.
East Hill Management Company, LLC
East Hill Management Company is an investment advisory firm specializing in alternative assets for high-net-worth investors and endowments, with a particular focus on life sciences and physical sciences spinouts from academic institutions.
What's next for Oxitec?
With the recent major strategic investment, Oxitec is well-positioned to scale its operations and expand the global reach of its groundbreaking pest control technology. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and support market penetration in key regions grappling with vector-borne diseases. The company's trajectory suggests a focus on commercialization and broader adoption of its sustainable insect control solutions, potentially leading to significant public health impacts.
See full Oxitec company page
